Table 4.
DALYs averted and additional cost of implementing a combination of interventions between 2010 and 2030
| DALYs averted (million) | Additional cost relative to baseline (2013; million US$) | ICER* | ACER† | |
|---|---|---|---|---|
| Facilitated linkage | 0·10 | $39·75 | $383·97 | $383·97 |
| Facilitated linkage and on-ART outreach | 0·81 | $406·78 | $518·30 | $501·17 |
| Facilitated linkage, on-ART outreach, and VCT point-of-care CD4 | 0·88 | $457·03 | $783·02 | $521·82 |
| Facilitated linkage, on-ART outreach, VCT point-of-care CD4, pre-ART outreach | 1·09 | $623·33 | $774·53 | $571·57 |
| Facilitated linkage, on-ART outreach, VCT point-of-care CD4, pre-ART outreach, and point-of-care CD4 | 1·10 | $630·99 | $543·24 | $571·21 |
| Facilitated linkage, on-ART outreach, VCT point-of-care CD4, pre-ART outreach, point-of-care CD4, and immediate ART | 1·68 | $1123·06 | $852·10 | $667·64 |
Intervention results in table 3 cannot be combined additively to arrive at those listed above because these results are generated with a dynamic model. Interventions were considered cost-effective if ACER was less than 50% of GDP per capita for Kenya in 2013 (US$1242).24 DALY=disability-adjusted life-year. ICER=incremental cost-effectiveness ratio. ACER=average cost-effectiveness ratio. ART=antiretroviral therapy. VCT=voluntary counselling and testing.
*
Cost per DALY averted compared with previous increment.
†
Cost per DALY averted compared with baseline.